

A Type 2 Diabetes Clinical Research Study

MB102077 is a phase 3 clinical research study for adults who take medication for both type 2 diabetes and high blood pressure – but still have blood pressure and sugar levels that are uncontrolled.

Objectives

Bristol-Myers Squibb is sponsoring this study to evaluate different doses of an investigational oral antidiabetic medication called dapagliflozin in adults with type 2 diabetes and high blood pressure.

Study Conduct and Design

MB102077 will include approximately 765 adults at research centers located in North America, South America, Europe, and India. Study participation is expected to be approximately 13 weeks.

Study volunteers will be randomly assigned into 1 of 3 groups and will receive ONE of the following:

- Dapagliflozin (5 mg)
- Dapagliflozin (10 mg)
- Placebo (inactive tablet)

In addition, study volunteers in all 3 groups will continue taking their current regimen of oral antidiabetic medication and blood pressure medication.

This study is double-blinded, which means neither the volunteer nor the study doctor, nor any of the research staff, knows which study medication the volunteer is receiving, except in an emergency.

over

Eligibility

You may be eligible to participate if you:

- Are between the ages of 18 and 89
- Have type 2 diabetes
- Are taking an oral antidiabetic medication
- Are taking blood pressure medication – either:
 - angiotensin-converting enzyme (ACE) Inhibitor **or**
 - angiotensin receptor blocker (ARB)
- Are taking an additional blood pressure medication:
 - thiazide/thiazide-like diuretic **or**
 - calcium channel blocker, beta blocker, alpha adrenergic blocker, **or** central alpha adrenergic agonist
- Have inadequately controlled blood sugar levels
- Have inadequately controlled high blood pressure

To learn more about this clinical research study, please talk to your doctor.